|
000
| 02165nam 2200349zi 4500 |
|---|
| 001 | 9.909644 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107181944 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 220330e202204##onc o f000 0 eng d |
|---|
| 020 | |a9780660428260 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-303/2022E-1-PDF |
|---|
| 245 | 00|aGuidance document : |bspecial access program for drugs : guidance document for industry and practitioners. |
|---|
| 246 | 10|aSpecial access program for drugs : |bguidance document for industry and practitioners |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cApril 2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (31 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Effective date: 2020/09/30 ; revised date: 2022/04/11." |
|---|
| 500 | |aIssued also in French under title: Ligne directrice : programme d’accès spécial aux médicaments : ligne directrice à l’intention de l’industrie et des praticiens. |
|---|
| 520 | |a"Health Canada’s Special Access Program for drugs (SAP) enables drugs that are not marketed in Canada to be requested by practitioners for the treatment, diagnosis, or prevention of serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. Non-marketed drugs may be unauthorized if they have not been approved by Health Canada. This means they have not been assessed for safety, effectiveness and quality. It may also mean that the sale of the drug has not commenced in Canada, or the product has been discontinued or removed from the market due to regulatory actions under the Food and Drug Regulations (FDR)"--Introduction, page 7. |
|---|
| 650 | 0|aDrug accessibility|xGovernment policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLigne directrice : |w(CaOODSP)9.909645 |
|---|
| 795 | |tGuidance document : |w9.906448 |
|---|
| 856 | 40|qPDF|s405 KB|uhttps://publications.gc.ca/collections/collection_2022/sc-hc/H164-303-2022-eng-1.pdf |
|---|